This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Photo Illustration of the new Wegovy semaglutide tablets with injectable prescription weight ...

The story of GLP-1 drugs keeps getting bigger. First they transformed the treatment of diabetes. Then they upended the science - and culture - of weight loss. Now a growing body of research is raising ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Lung cancer is among the conditions that may be affected. GLP-1 medications such as Wegovy, ...

Popular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference. Research led by Cleveland ...

GLP-1 medications offer cancer survivors a tool to manage treatment-related weight gain through coordinated care. If you've finished cancer treatment and found yourself struggling with weight changes ...

New research seems to link the use of GLP-1 (Ozempic, Wegovy, and Zepbound) with better breast cancer outcomes. Scientists don't yet know why this is — it may not be the medications themselves, but ...

SAN DIEGO — Weight loss, type 2 diabetes, sleep apnea, liver disease, heart disease … cancer? Drugs like Ozempic can help treat a variety of health conditions, but the portrait of their effects in ...

“The data we're seeing on GLP-1s and cancer risk reduction is exciting, and medical oncologists are watching it closely,” says Dr. Rahul Gosain, an oncologist and co-host of The Oncology Brothers.

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting. The list of ...

GLP-1 medications carry a boxed warning about the potential increased risk of thyroid cancer in some people. However, current clinical evidence also points to significant GLP-1 cancer benefits. In ...

CHICAGO—At the world’s largest oncology conference, Ozempic, a diabetes drug, found its way to the center of the conversation. As thousands of attendees bounced between presentations at the American ...